Zhejiang Huakang Pharmaceutical Co (SHSE:605077) Piotroski F-Score: 6 (As of Jul. 30, 2026) — 50% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605077 Zhejiang Huakang Pharmaceutical Co Ltd SHSE:605077
73 GF Score
Price ¥10.90
GF Value ¥39.70
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Zhejiang Huakang Pharmaceutical Co Piotroski F-Score?

Zhejiang Huakang Pharmaceutical Co SHSE:605077 -0.64% 73 Piotroski F-Score is 6 as of Jul. 30, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates SHSE:605077 with a GF Score™ of 73/100 and a GF Value™ of ¥39.70 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,558 Chemicals companies, Zhejiang Huakang Pharmaceutical Co ranks better than 75.99% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhejiang Huakang Pharmaceutical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Zhejiang Huakang Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SHSE:605077' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 6

During the past 10 years, the highest Piotroski F-Score of Zhejiang Huakang Pharmaceutical Co was 7. The lowest was 2. And the median was 4.

Zhejiang Huakang Pharmaceutical Co  (SHSE:605077) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zhejiang Huakang Pharmaceutical Co Piotroski F-Score Related Terms


Zhejiang Huakang Pharmaceutical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Zhejiang Huakang Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Huakang Pharmaceutical Co Piotroski F-Score Chart

Zhejiang Huakang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 3.00 5.00 3.00 6.00

Zhejiang Huakang Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 4.00 6.00 6.00

SHSE:605077 vs DOW: Piotroski F-Score Comparison

For the Chemicals subindustry, Zhejiang Huakang Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Huakang Pharmaceutical Co Piotroski F-Score vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Zhejiang Huakang Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zhejiang Huakang Pharmaceutical Co's Piotroski F-Score falls into.


SHSE:605077
73GF Score
Zhejiang Huakang Pharmaceutical Co Ltd SHSE:605077
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 52.668 + 34.676 + 31.918 + 22.171 = ¥141 Mil.
Cash Flow from Operations was 118.462 + 250.911 + 90.324 + -31.2 = ¥428 Mil.
Revenue was 1049.314 + 1093.165 + 1229.724 + 1186.819 = ¥4,559 Mil.
Gross Profit was 173.726 + 139.457 + 157.84 + 135.152 = ¥606 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(7605.587 + 7564.597 + 7761.48 + 8039.933 + 8081.839) / 5 = ¥7810.6872 Mil.
Total Assets at the begining of this year (Mar25) was ¥7,606 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2,060 Mil.
Total Current Assets was ¥3,478 Mil.
Total Current Liabilities was ¥2,509 Mil.
Net Income was 58.382 + 48.533 + 81.57 + 81.038 = ¥270 Mil.

Revenue was 723.927 + 747.063 + 702.63 + 816.548 = ¥2,990 Mil.
Gross Profit was 141.573 + 145.81 + 171.584 + 158.43 = ¥617 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(6271.911 + 5971.725 + 6192.178 + 6992.029 + 7605.587) / 5 = ¥6606.686 Mil.
Total Assets at the begining of last year (Mar24) was ¥6,272 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2,260 Mil.
Total Current Assets was ¥3,138 Mil.
Total Current Liabilities was ¥1,773 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhejiang Huakang Pharmaceutical Co's current Net Income (TTM) was 141. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhejiang Huakang Pharmaceutical Co's current Cash Flow from Operations (TTM) was 428. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=141.433/7605.587
=0.01859593

ROA (Last Year)=Net Income/Total Assets (Mar24)
=269.523/6271.911
=0.04297303

Zhejiang Huakang Pharmaceutical Co's return on assets of this year was 0.01859593. Zhejiang Huakang Pharmaceutical Co's return on assets of last year was 0.04297303. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zhejiang Huakang Pharmaceutical Co's current Net Income (TTM) was 141. Zhejiang Huakang Pharmaceutical Co's current Cash Flow from Operations (TTM) was 428. ==> 428 > 141 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=2059.514/7810.6872
=0.26367898

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=2260.426/6606.686
=0.34214219

Zhejiang Huakang Pharmaceutical Co's gearing of this year was 0.26367898. Zhejiang Huakang Pharmaceutical Co's gearing of last year was 0.34214219. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=3478.176/2509.332
=1.38609638

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=3138.411/1773.428
=1.76968617

Zhejiang Huakang Pharmaceutical Co's current ratio of this year was 1.38609638. Zhejiang Huakang Pharmaceutical Co's current ratio of last year was 1.76968617. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zhejiang Huakang Pharmaceutical Co's number of shares in issue this year was 201.559. Zhejiang Huakang Pharmaceutical Co's number of shares in issue last year was 368.352. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=606.175/4559.022
=0.13296163

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=617.397/2990.168
=0.20647569

Zhejiang Huakang Pharmaceutical Co's gross margin of this year was 0.13296163. Zhejiang Huakang Pharmaceutical Co's gross margin of last year was 0.20647569. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=4559.022/7605.587
=0.59943066

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=2990.168/6271.911
=0.47675549

Zhejiang Huakang Pharmaceutical Co's asset turnover of this year was 0.59943066. Zhejiang Huakang Pharmaceutical Co's asset turnover of last year was 0.47675549. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhejiang Huakang Pharmaceutical Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Zhejiang Huakang Pharmaceutical Co (SHSE:605077) has a Piotroski F-Score of 6 as of Jul. 30, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zhejiang Huakang Pharmaceutical Co and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Zhejiang Huakang Pharmaceutical Co's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Zhejiang Huakang Pharmaceutical Co ranks #374 out of 1558 companies in the Chemicals industry, placing it in the top 24%.
Is Zhejiang Huakang Pharmaceutical Co's Piotroski F-Score too high?
Zhejiang Huakang Pharmaceutical Co's current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Chemicals industry median Piotroski F-Score is 5.00. Zhejiang Huakang Pharmaceutical Co's value of 6 is 20% above this industry median. Based on the distribution chart, Zhejiang Huakang Pharmaceutical Co ranks #374 out of 1558 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Huakang Pharmaceutical Co has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Huakang Pharmaceutical Co's Piotroski F-Score compare to DOW?
According to the Chemicals industry distribution chart, Zhejiang Huakang Pharmaceutical Co ranks #374 out of 1558 companies for Piotroski F-Score. This places Zhejiang Huakang Pharmaceutical Co in the top 24% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Zhejiang Huakang Pharmaceutical Co's value of 6 is 20% above this benchmark. Historically, Zhejiang Huakang Pharmaceutical Co's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Zhejiang Huakang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Chemicals company?
The median Piotroski F-Score among Chemicals companies is 5.00, based on 1,558 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Huakang Pharmaceutical Co's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zhejiang Huakang Pharmaceutical Co and its competitors. For the Chemicals industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Huakang Pharmaceutical Co's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Huakang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Huakang Pharmaceutical Co (SHSE:605077) is currently considered Possible Value Trap. The stock's GF Value™ is ¥39.70, compared to a current price of ¥10.90 — trading 72.5% below its estimated fair value. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 20% above the Chemicals industry median of 5.00. Zhejiang Huakang Pharmaceutical Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Zhejiang Huakang Pharmaceutical Co (SHSE:605077), the current Piotroski F-Score is 6 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Huakang Pharmaceutical Co (SHSE:605077) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Huakang Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥10.90 is trading 72.5% below its estimated GF Value™ of ¥39.70. GuruFocus considers Zhejiang Huakang Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for SHSE:605077:

  • Piotroski F-Score: 6 (50% above median its 10-year median of 4.00)
  • GF Value™: ¥39.70 vs. price of ¥10.90 (72.5% below fair value)
  • GF Score™: 73/100 with 7 warning signs
  • Industry Position: 20% above the Chemicals median (#374 of 1558)

No single metric tells the full story. See the SHSE:605077 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Huakang Pharmaceutical Co Business Description

Address No. 18, Huagong Road, Huabu Town, Zhejiang Province, Kaihua County, Quzhou, CHN, 324302
Zhejiang Huakang Pharmaceutical Co Ltd is engaged in the research and development, production and sales of various functional sugar alcohols and starch sugar products such as xylitol, sorbitol, maltitol, fructose syrup and others.
73GF Score

Get the complete analysis for SHSE:605077

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥10.90
Price
¥39.70
GF Value